Trial 7H-22-2


A Phase II Open Label, Single Arm Study to Evaluate the Efficacy of Pembrolizumab for Leukoplakia

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Mark Swanson, M.D.
Other Trial Staff:  Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Anisa Sandin, Coordinator, Andrew Zeng, Coordinator, Thomas Won, D.M., Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.